Objectives: Major depression is associated with reduced cardiac vagal control, most commonly indexed by heart rate variability. To examine the dynamics of this abnormality, we examined within-participant covariation over time between brain activity, cardiac vagal control, and depressive symptoms in depressed patients treated with sertraline and in healthy volunteers.
INTRODUCTION M
ajor depressive disorder (MDD) is commonly associated with abnormalities in subgenual anterior cingulate cortex (sgACC), rostral ACC (rACC), dorsal ACC (dACC), and subcortical regions including the hypothalamus, periaqueductal gray area (PAG), and other brainstem nuclei (1, 2) . These regions participate in a larger network implementing vagal control, termed the medial visceromotor network (MVN), and are central to the regulation of autonomic and neuroendocrine responses (1, 3, 4) . Although MVN regions play an important role in governing mood (5, 6) and are crucial for effective emotion regulation (7, 8) , the contribution of activity within the MVN to autonomic regulation in the context of depression and its treatment is not well understood (9) (10) (11) (12) (13) .
The sgACC and rACC are two critical hubs in the MVN, and a variety of functional imaging studies implicate ACC dysfunction as a core feature of the neural basis of depression (7, (14) (15) (16) . Patients with MDD tend to manifest hyperactivity in sgACC (17) , and successful treatment of depression with deep brain stimulation of sgACC is associated with corresponding down-regulation of sgACC (18) . The sgACC is a principal site of converging autonomic signals in the neocortex and paralimbic cortex and plays a central role in autonomic regulation (19, 20) . Although important for autonomic regulation, rACC and dACC have stronger connections to each other and medial prefrontal cortex (mPFC) compared with sgACC, suggesting that they may have a greater role in cognitive control and emotional regulation (16) . Activation of dACC is associated with regulation of negative affect and conflict resolution (21, 22) , both of which are impaired in MDD (14, 21) . Higher resting activity in rACC before treatment is predictive of successful antidepressant treatment outcomes across multiple studies (16) , and failure to deactivate rACC while evaluating emotional pictures is associated with greater depressive symptoms (7) .
To assess vagal control in the periphery, we focused on relationships between brain activity and dynamic parasympathetic control over heart rate. Functional reductions in parasympathetic control of heart rate have been observed in depression (23) (24) (25) (26) (27) and anxiety (20, 28) , as indexed by high frequency heart rate variability (29) , which reflects respiratory-linked changes in heart rate known as respiratory sinus arrhythmia (RSA). Although normalization of RSA has been associated with successful treatment of depression (30) (31) (32) , selective serotonin reuptake inhibitor (SSRI) treatment is not generally associated with significant improvement in RSA (32) . RSA can be assessed continuously in the functional magnetic resonance imaging (fMRI) environment and is a particularly useful measure for exploring the covariation of brain activity, depressive symptoms, and autonomic function over the course of antidepressant treatment.
In healthy volunteers, RSA correlates positively with coincident activity of multiple structures within the MVN, including rACC, sgACC, dACC, insula, striatum, PAG, and hypothalamus (33) (34) (35) (36) (37) (38) . Dysfunction within the MVN has been observed in the few functional neuroimaging studies that have examined RSA in relation to depression (17, 39, 40) , but a neuroimaging study that examines the association between brain activity and RSA in the context of antidepressant treatment has not been undertaken.
We conducted a preliminary study to examine the change in covariation between the time course of the fMRI blood oxygen level-dependent (BOLD) signal and RSA at each of four different visits during a 12-week treatment course. Depressed patients and nondepressed control participants were scanned at baseline and at 2, 6, and 12 weeks after baseline (Week 0) assessment. We predicted that in healthy controls, the covariation between RSA and MVN regions would be positive at each assessment and remain stable across assessments. Given reduced RSA in depression, we predicted that covariation between RSA and vagal control regions would initially be reduced for patients compared with controls and that BOLD-RSA covariation would increase with successful treatment. Given the importance of the ACC regions in autonomic regulation and their known dysfunction in depression, we were particularly interested in how BOLD-RSA covariation in the sgACC, dACC, and rACC evolved with treatment.
METHODS AND MATERIALS

Participants
Seventeen patients with MDD were recruited to participate in a 12-week study on the relationship between depression treatment and physiological health. Seven patients withdrew from the study before completing the final session, and 10 patients completed all portions of the study. Twenty subjects (10 with MDD: age = 36.8 [9.3] years, 9 women; 10 controls: age = 35.6 [12. 3], 9 women; values represented as mean[standard deviation] here and elsewhere, unless otherwise specified) participated in four separate f MRI sessions each, across 12 weeks. Of the 10 patients who completed the study, 3 were excluded due to artifacts in the electrocardiographic (ECG) recording at baseline. Thus, the final sample contained 17 participants (7 with MDD: age = 35.6[8.0] years, 7 women; 10 controls: age = 35.6 [12. 3] years, 9 women). Patients with MDD were recruited from the Depression Clinic in the Department of Psychiatry as well as via newspaper and radio advertising. All patients met the criteria for MDD; diagnosis was established at intake based on scores from the MINI International Neuropsychiatric Interview and the Hamilton Depression Inventory. All patients scored at least 16 on the Hamilton Depression Inventory, and no controls scored more than 1. A trained clinician blind to group made weekly clinical ratings of depressive symptoms using the Montgomery Asperg Depression Rating Scale (MADRS) and additional Beck Depression Inventory measurements at each f MRI session (Weeks 0, 2, 6, and 12). Patients with MDD were not taking antidepressant medication before study participation, nor were they currently engaged in a psychotherapy program. MDD patients with comorbidities other than anxiety (e.g., psychosis and substance abuse) were excluded. Three of the seven patients with MDD included in the study also had an anxiety disorder. Control participants were recruited via on-campus advertising at the University of Arizona. The Human Subjects Protection Program at the University of Arizona approved all procedures and protocols, and all participants provided informed consent.
Procedures
All participants returned once per week during the full 12-week course of the study for an evaluation of depressive symptoms. Each week, patients with MDD also met with a study psychiatrist who, based on a prespecified protocol, modified the daily dose of sertraline between the initial dose of 50 mg and a maximum of 200 mg based on MADRS scores.
All patients participated in the f MRI portion of the experiment on four occasions: Weeks 0, 2, 6, and 12. Weeks 0 and 12 were selected to examine the effects of sertraline on BOLD-RSA interactions before and after treatment. Scanning at Week 2 was motivated by evidence that, typically, SSRIs induce neurochemical changes at this point, although symptom improvement is generally absent or minimal (41) . Scanning occurred at Week 6 because at that point, many patients who will be treatment responsive show substantial symptom relief.
Data Acquisition
Respiratory Sinus Arrhythmia
Continuous ECG was obtained in synchrony with f MRI using the In Vivo 3150 M Magnitude MRI Patient Monitor, a multilead ECG with digital signal processing filtering for removal of MRI gradient artifact. The timing of each beat (R-spike) was first identified using QRSTool (42) then hand edited to correct for missed, extra, or ectopic beats. The resultant interbeat interval (IBI) series was used for calculating RSA in a series of overlapping windows of 16 seconds each, offset by 3 seconds to correspond to the f MRI repetition time (TR). For each window, RSA was calculated as the natural log of the variance of the bandpass filtered (0.12-0.40 Hz) IBI time series (interpolated at 10 Hz). If an artifact prevented the reliable determination of a single beat, that beat was interpolated. If the artifact obscured two or more consecutive beats, the period was truncated to the last usable beat. The result was an RSA time series, with one RSA value for each TR, reflecting the respiratory-linked variance in IBIs for the period beginning 8 seconds before the TR and extending 8 seconds after the start of the TR (Fig. 1 ). Each RSA series was high-pass filtered at 1/190 Hz to match the filtering of the f MRI data.
Functional Magnetic Resonance Imaging
f MRI data were acquired in the coronal plane from a 3.0-T GE Signa VH/I system with an 8-channel head coil at the University of Arizona. Scan parameters for the gradient echo spiral in-out pulse sequence were as follows: TR = 3000 milliseconds, echo time = 30 milliseconds, flip angle = 90°, field of view = 22 cm, 64 Â 64 matrix, and 3-mm-thick slices. A structural MPRAGE scan was obtained at each session. Six functional scans were acquired during three different affective tasks that consisted of implicit processing of emotional cues (faces) (43) , processing of emotion cues (words) in the attentional background (44) (45) (46) , and processing of emotional cues (pictures) in the attentional foreground (47) (two scans each: 99-106 images per scan, 620 images per week). The duration of each functional imaging session was 31 minutes, 24 seconds. The three tasks were designed to elicit implicit, background, and explicit emotional responses, respectively. Task-related activity is being analyzed separately; the purpose of this article was to investigate brain-RSA correlation across all tasks. All f MRI images were preprocessed using SPM8 and warped onto a standard neurological template (MNI). In the final preprocessing step, denoised functional images were generated by removing variance in the data explained by motion parameter estimates and their squared values, gradient (derivative) values, and squared gradients, as well as any outlier volumes identified via Mahalanobis distance (48) . Scanning data were collected over a 3-year period, beginning with the first scan in March 2007 and ending with the final scan in February 2010.
Analysis
Respiratory Sinus Arrhythmia
Overall differences in mean RSA values during each scanning session were compared across groups, and differences in the change of mean RSA over the entire study were compared across groups using a between-group t test on the within-participant linear change of mean RSA over time.
Functional Magnetic Resonance Imaging
Each denoised image series was correlated voxel-by-voxel with the corresponding RSA series. The first two analyses focused on 10 predetermined regions of interest (ROIs). Seven ROIs were drawn around reported functional clusters from a meta-analysis of RSA and affective states (38) , and reported functional clusters correlated with RSA during nonaffective working memory tasks (35) . An additional three anatomical ROIs were generated for MVN regions not identified in the previous studies (dACC, PAG, hypothalamus) by searching anatomical keywords in NeuroSynth, a freely available meta-analysis tool (49) ( Table 1) .
Mean ROI Analysis
The covariation between RSA and BOLD was averaged across voxels within each ROI within each week, so that a single value represented the BOLD-RSA covariation for each participant in each ROI for each week. This method has the two-fold benefit of a) permitting planned analyses without requiring multiple comparisons correction if all areas are specified a priori and reported, as they are here, and b) reducing residual and random error in estimates of BOLD-RSA covariation within each ROI by averaging across many voxels, which improves our ability to detect between-group variation and overall changes over time. When estimating FIGURE 1. RSA moving window analysis. The differently shaded rectangles represent the first three time segments over which the RSA value was derived. In this example, these three values were then compared with fMRI BOLD signal recorded at 9, 12, and 15 seconds from the onset of scanning, respectively. RSA = respiratory sinus arrhythmia; fMRI = functional magnetic resonance imaging; BOLD = blood oxygen level dependent; TR = repetition time. Color image is available only in online version (www.psychosomaticmedicine.org).
change in BOLD-RSA across weeks, we estimated the linear change within each participant and tested whether this change was different between patients and controls. These changes were analyzed across participants using the "lme4" package in R, allowing the within-participant intercepts and slopes to vary as random effects. The planned analysis was to aggregate all data across the three tasks into a single measure. However, we also completed three post hoc analyses in which we examined linear change in BOLD-RSA covariation within each task. Significant findings are reported at p < .05.
Nonparametric Analysis
To supplement analysis of ROI averages and examine the spatial extent of BOLD-RSA covariation within each ROI at baseline and posttreatment, we used a nonparametric permutation test to estimate the distribution of null hypothesis t values within each ROI (10,000 iterations) and applied smallvolume correction to identify significant voxels. We repeated this analysis on the within-participant linear contrast image of the covariation patterns across weeks to identify the spatial extent of BOLD-RSA increases over time in patients compared with controls. In addition, we used nonparametric methods to examine relationships between MADRS scores and individual differences in BOLD-RSA covariation in patients at baseline and posttreatment. Significant results are reported at p < .05, small volume corrected.
Whole-Brain Analysis
The final analysis was a whole-brain analysis designed to identify other brain regions where covariation between activity and RSA may improve with treatment. We set the primary criterion threshold to p < .001 uncorrected and report as significant all regions with a significant cluster corrected level of p < .05 (50) . For completeness, we also report clusters that are significant at p < .001 uncorrected but fail to reach clustercorrected significance. Although the results in these clusters cannot be fully interpreted, they may be useful in determining a priori ROIs for future studies.
RESULTS
Behavior
At intake, patients had an average MADRS value of 21.5 (7.0) that significantly dropped to 10.9(10.5) posttreatment (pretreatment versus posttreatment: t 6 = −3.67, p = .011). As anticipated, mean RSA was lower in patients compared with controls (t 15 = −1.91, p = .037, one tailed). This difference did not significantly change over time (t 15 = 1.58, p = .14). RSA measures during follow-up are shown in Table S1 , Supplemental Digital Content 1, http://links.lww.com/PSYMED/A221, and indicate no significant changes over time for the sertraline-treated group or the control group.
Functional Magnetic Resonance Imaging
Mean ROI Analysis
At baseline, we observed lower BOLD-RSA covariation in patients compared with controls in L insula (t 15 = −2.24, p = .041). In addition, there was marginal evidence for lower BOLD-RSA covariation in rACC (t 15 = −2.09 p = .054) and dACC (t 15 = −1.96 p = .069). Posttreatment, there were no significant differences in BOLD-RSA covariation between groups within any ROI (Fig. 2) . (Fig. 2) . When analyzed by task, patients had significantly greater increases in BOLD-RSA covariation within L insula (t 15 = −2.94, p = .011), rmPFC (t 15 = −2.32, p = .035), and L Amy (t 15 = −2.78, p = .015) and marginally greater increases in dACC (t 15 = −1.89, p = .08) during the pictures task, marginally greater increases within L Amy (t 15 = −2.07, p = .057) during the faces task, and marginally greater increases in PAG (t 15 = −1.90, p = .079) during the words task.
Nonparametric Analysis
There was a significantly less positive BOLD-RSA covariation at baseline for patients compared with controls in R rACC, R sgACC, L putamen, and L insula (Fig. 3A) . Posttreatment, patients had greater BOLD-RSA covariation than did controls in sgACC (Fig. 3B) . Across the entire study, patients had greater increases compared with controls in BOLD-RSA covariation within sgACC, rACC, putamen, Amy, insula, dACC, and PAG (Fig. 3C) . For depressed patients, increases in BOLD-RSA covariation with treatment within PAG and hypothalamus were correlated with improvement in MADRS (Table 1) .
Whole-Brain Analysis
The increase in BOLD-RSA covariation over the four sessions was significantly greater for patients with MDD than for controls within the midbrain, medial thalamus, and R putamen (cluster-corrected p < .05), indicating a shift to stronger positive brain-RSA correlations in patients over the course of treatment (Fig. 4) . Group differences significant to p < .001 uncorrected are included for display purposes and listed in Table S2 
DISCUSSION
This is the first study to longitudinally examine correlations between brain activity and autonomic function across the course of antidepressant treatment. In multiple brain areas, including key nodes in the MVN, a consistent pattern was observed in which the covariation between RSA and BOLD activity increased with treatment in depressed patients while largely remaining constant in healthy FIGURE 2. Mean BOLD-RSA covariation. Mean covariation as assessed by BOLD-RSA correlations normalizes during treatment for patients with MDD and remains relatively stable for controls. Change in BOLD-RSA covariation is significantly greater for patients compared with controls in sgACC, dACC, PAG, L insula, putamen, and L Amy (* p < .05). Error bars are ±SEM. BOLD = blood oxygen level dependent; RSA = respiratory sinus arrhythmia; ACC = anterior cingulate cortex; sgACC = subgenual ACC; dACC = dorsal ACC; PAG = periaqueductal gray area; Amy = amygdala; SEM = standard error of the mean; rACC = rostral ACC; PFC = prefrontal cortex; vmPFC = ventromedial PFC; rmPFC = rostromedial PFC. Color image is available only in online version (www.psychosomaticmedicine.org).
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The lower baseline BOLD-RSA covariation and treatmentrelated increases in BOLD-RSA covariation over time in depressed participants suggest that the depressed state is associated with an alteration in brain regulation of cardiac vagal control at baseline. The brain areas that show increased BOLD-RSA covariation also participate in the emotion dysregulation that characterizes depression. It therefore seems that response to antidepressant treatment involves changes in regional brain function associated with both emotion and autonomic regulation.
These changes in brain-RSA relationships across sessions may be a stronger correlate of changes in depression than changes in RSA itself. A recent meta-analysis reaffirmed that RSA is lower in depression but also found that SSRI treatment is typically not associated with increased RSA despite effectively reducing symptoms of depression (32) . Consistent with these findings, we observed diminished RSA in depressed patients that persisted despite effective treatment. Given that we observed significant normalization in the relationship between brain activity and RSA as depression abated, a key question is why RSA did not increase significantly during treatment. There are several potential reasons.
One hypothesis is that the SSRI-induced changes in the MVN were insufficient to induce significant change in RSA, implying that the brain-RSA changes are more sensitive to treatment than RSA changes overall. Although prominent changes were observed in the insula and the insula is part of the MVN, the specific insula ROI drawn from the literature covers a region primarily connected to lower level viscerosensory regions (51, 52) . However, positive shifts in BOLD-RSA covariation with treatment were observed in visceromotor ROIs, such as PAG and ventromedial putamen (53) , as well as in sgACC and dACC, which have at least some visceromotor effects on RSA. Voxel-wise differences in BOLD-RSA covariation within ROIs. Green shading marks ROI extent where no differences were observed between groups. A, Week 0 (baseline, patients − controls): before treatment, patients show a significantly reduced BOLD-RSA covariation compared with controls in rACC, sgACC, insula, and putamen. B, Week 12 (study completion, patients − controls): patients show a significantly increased BOLD-RSA covariation compared with controls in sgACC after treatment. C, Change over time (patients − controls): over the course of the study, increases in BOLD-RSA covariation are greater for patients than for controls within sgACC, rACC, putamen, Amy, insula, dACC, and PAG. BOLD = blood oxygen level dependent; RSA = respiratory sinus arrhythmia; ACC = anterior cingulate cortex; rACC = rostral ACC; sgACC = subgenual ACC; Amy = amygdala; dACC = dorsal ACC; PAG = periaqueductal gray area; PFC = prefrontal cortex; vmPFC = ventromedial PFC; rmPFC = rostromedial PFC.
Thus, although some visceromotor areas were affected by SSRI treatment, the changes observed were somehow insufficient to measurably change RSA.
Within the ROIs examined, it is notable that we failed to find overall increases in covariation within the rACC. The rACC in particular possesses monosynaptic connections to hypothalamus and PAG (1) that, when stimulated, have immediate cardiovascular effects (3, 4) . Because both mean RSA and overall rACC activity fail to normalize after a successful antidepressant treatment in this and another study (54) , this suggests that the two may be related, although the failure to detect a change in the case of both variables may be due to a lack of power. Although this study is unable to test that hypothesis, other therapies that improve function in rACC may be able to examine whether improvements in rACC function and RSA function are related. Some evidence is available that psychotherapy such as cognitive behavioral therapy (CBT) increases activity in cortical structures including dACC and rACC (55) and thus potentially recruits visceromotor output centers within the MVN more fully compared with treatment with SSRIs. To our knowledge, a longitudinal study of changes in RSA (or other indices of heart rate variability) during CBT has not been conducted. It is possible that cognitive processes enhanced by CBT engage rACC and rmPFC to a greater degree than SSRIs and may thereby promote greater change in RSA.
The combination of medication and psychotherapy is more effective than either modality alone (56) . Perhaps this is true because the combination of treatments promotes completion of a feedback loop whereby both afferent and efferent neurotransmissions are promoted in a recursive fashion. It is possible, although not yet demonstrated, that RSA is restored when remission occurs, consistent with the observation that depression severity and RSA are inversely correlated (31) .
An important implication of this research on brain mechanisms of vagal control in depression involves the 1.5-to 3-fold greater mortality in coronary artery disease in depressed versus nondepressed individuals (9) . The mechanisms underlying the relationship between depression and mortality are not clear. One possible mechanism is reduced vagal control, which is known to increase myocardial electrical instability and sudden cardiac death (57) . Reduced vagal control could contribute to hyperarousal and the insomnia associated with depression. Reduced vagal control, as well as insomnia, is associated with elevation in inflammation (57) (58) (59) , which can contribute to the progression of coronary artery disease. It is known that the somatic symptoms of depression confer increased risk for mortality, which would be consistent with these mechanisms (60) . These data raise the possibility that depression treatments that normalize function within visceromotor brain regions may be cardioprotective, as they could lead to overall increased vagal control.
Limitations and Future Directions
Although the findings in this study are robust, there are several limitations. a) The sample is almost entirely composed of female participants. Future studies should be more balanced across sex to generalize findings to all patients. b) A number of patients dropped out of the study either due to response or nonresponse to treatment. Virtually all of the remaining depressed participants who completed the study (and who were included in this analysis) were treatment responders. A larger study is needed to compare the time course and extent of BOLD-RSA covariations in remitters, responders, and nonresponders. c) The findings reported here may be a function of improvement in the depressed state in general rather than SSRI treatment in particular. This could be addressed in future studies by including alternative depression treatments such as CBT or other antidepressants. Placebos are also associated with significant antidepressant effects (61) that are based on changes in emotion regulatory centers in the brain (62) . In future studies, comparison of the effects of antidepressants, CBT, and placebos on BOLD-RSA covariation is needed. d) The sample size is smaller than is typically desired. However, each patient included in the study participated in four separate sessions, allowing us to test for group differences using repeated measures. This substantially increased our power to detect changes in BOLD-RSA covariation over time by accounting for more error, with an estimated 70% to 80% chance of detecting a moderate effect (using estimates of session-to-session variance derived from control participants) for this within-participant design, compared with an estimated 30% to 40% chance of detecting an effect were each of the data points collected from separate participants.
The concept that SSRIs do not fully normalize function within the MVN necessitates future testing of the following hypotheses. a) Antidepressant treatment regimens that engage primary output structures of the MVN (e.g., rACC) more fully than SSRIs, such as CBT or CBT combined with SSRIs, may be more likely to result in RSA increases than are treatments that do so to a lesser extent. b) Greater increases in BOLD-RSA covariation in rACC and rmPFC with treatment will be correlated with greater subsequent increases in RSA and inversely correlated with the likelihood of relapse; and c) reduced RSA may be related to cardiovascular disease risk in remitted and currently depressed individuals.
Summary
The normalization of BOLD-RSA covariation observed at the 12-week assessment may be an indicator of successful antidepressant treatment outcome. However, the lack of change in RSA with SSRI treatment implies that SSRI treatment only leads to partial improvement in visceromotor mechanisms. It remains untested whether improvement in RSA occurs with more effective SSRI treatment (e.g., remission rather than response) or whether improvement in RSA normalizes at some point after normalization of BOLD-RSA covariation. These findings lead to novel predictions about the mechanisms by which combined psychotherapy and pharmacotherapy may exert greater clinical effects including protection against cardiac morbidity and depressive relapse. 
